Aurobindo breaks ground on New Jersey facility

pills

Aurobindo is starting to build on its pledge to expand operations in New Jersey, literally.  

The Indian drugmaker this week broke ground on the 567,000-square-foot facility that is slated to include a manufacturing and distribution center and warehouse, according to NJ.com. The company has said it expects to eventually have 400 to 500 jobs there.

The expansions come as Aurobindo is building its business in the U.S. It has said that it has about 45 generic drug applications pending before the FDA.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

In addition to the New Jersey project, the drugmaker announced plans in April to spend $31.7 million to turn a former medical facility in Durham, NC, into a manufacturing site. When complete, that project is slated to have 275 workers.

The drugmaker said it decided it would be able to get expanded U.S. production faster by retrofitting a former Teleflex Medical facility near Research Triangle Park, than to build a new manufacturing facility at its New Jersey campus. Aurobindo has been approved for more than $4.6 million in state and local incentives for the North Carolina project.

- read the NJ.com story

Related Articles: 
Aurobindo moves forward with plans for new U.S. plant 
Aurobindo to move U.S. HQ, manufacturing to North Carolina 
FDA finds faults with one of two Aurobindo plants it inspects

Suggested Articles

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.

After a global scare over Zantac contamination, generic metformin could be next in line as regulators test for possible carcinogen contamination.

PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.